Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback